Palatin Technologies, Inc.(NYSE Amex Equities : PTN)
(
)
Volume
Open
Day's Low
Day's High
52 Wk Low
52 Wk High
Bid
Ask
EPS
PE Ratio
Shares
Market Cap
Dividend
Ex-Div Date
Yield
Interested in Gold Updates?
Receive the latest updates on the gold and silver markets.
...
Health Technology » Biotechnology
| symbol | company | %chng | last | %short | avg$volume | |
|---|---|---|---|---|---|---|
| MRNA | Moderna, Inc. | 1.59% | 154.96 | 0.0% | $1509.75m | |
| NVAX | Novavax, Inc. | 2.55% | 79.18 | 78.2% | $568.86m | |
| AMGN | Amgen, Inc. | -1.11% | 222.54 | 1.4% | $546.33m | |
| GILD | Gilead Sciences, Inc. | -2.18% | 67.34 | 1.0% | $534.08m | |
| BIIB | Biogen, Inc. | -1.22% | 219.60 | 1.8% | $496.23m | |
| BNTX | BioNTech SE | 2.69% | 160.70 | 0.0% | $493.59m | |
| REGN | Regeneron Pharmaceuticals, Inc. | 0.34% | 605.25 | 2.7% | $434.03m | |
| ILMN | Illumina, Inc. | -3.77% | 331.78 | 3.3% | $370.86m | |
| VRTX | Vertex Pharmaceuticals, Inc. | -0.23% | 226.58 | 1.9% | $358.72m | |
| SNSS | Sunesis Pharmaceuticals, Inc. | -4.71% | 2.63 | 0.7% | $183.85m | |
| EXAS | EXACT Sciences Corp. | -0.42% | 68.89 | 17.9% | $173.71m | |
| INCY | Incyte Corp. | -0.85% | 73.52 | 2.4% | $141.06m | |
| ARNA | Arena Pharmaceuticals, Inc. | -0.29% | 89.63 | 13.7% | $135.69m | |
| BMRN | BioMarin Pharmaceutical, Inc. | -1.37% | 83.70 | 4.2% | $108.53m | |
| CRSP | CRISPR Therapeutics AG | -1.12% | 61.84 | 0.6% | $107.20m |
Company Profile
Palatin Technologies, Inc. is a biopharmaceutical company, which engages in the development of medicines based on molecules that modulate the activity of the melanocortin and natriuretic peptide receptor systems. Its primary product candidate is marketed under the Vyleesi brand, the trade name for bremelanotide, a peptide melanocortin receptor 4 agonist for the treatment of premenopausal women with acquired, generalized, hypoactive sexual desire disorder (HSDD). The company was founded by Carl Spana and John K. A. Prendergast on November 21, 1986 and is headquartered in Cranbury, NJ.